BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang ZH, Li LX, Li P, Lv SC, Pan B, He Q. Sirolimus in Liver Transplant Recipients with Hepatocellular Carcinoma: An Updated Meta-Analysis. J Invest Surg. 2018;1-10. [PMID: 29557691 DOI: 10.1080/08941939.2018.1447053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Grigg S, Gow PJ, Yeomans N. Letter: the effect of sirolimus on recurrence and survival in liver transplant recipients with hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:1330-1. [DOI: 10.1111/apt.14963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Wang DD, Chen X, Xu H, Li ZP. Initial Dosage Recommendation for Sirolimus in Children With Tuberous Sclerosis Complex. Front Pharmacol 2020;11:890. [PMID: 32595509 DOI: 10.3389/fphar.2020.00890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Grigg S, Gow P, Yeomans N. Sirolimus in Liver Transplant Recipients With Hepatocellular Carcinoma. J Invest Surg 2020;33:389-90. [PMID: 30457404 DOI: 10.1080/08941939.2018.1513103] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Su RY, Ling SB, Shan QN, Wei XY, Wang R, Jia CK, Zhuang L, Shen T, Ding LM, Xu ZD, Luo LB, Sun LB, Li GM, Fang TS, Jiang N, Zhang K, Su ZJ, Peng ZH, Lang R, Jiang T, He Q, Ye LS, Yang Y, He YT, Guo WZ, Lan LG, Sun XY, Chen D, Chen ZS, Zhou DW, Ye SJ, Ye QF, Tian M, Shi JH, Wang B, Liu J, Lu Q, Rao W, Cai JZ, Lv T, Yang JY, Wang PS, Zhong L, Ma JS, Li QG, Wu SD, Lu CJ, Lu CD, Zhang DH, Wang X, Li ZQ, Teng MJ, Li JJ, Jiang WT, Li JH, Zhang QB, Zhu NQ, Wang ZX, He K, Xia Q, Song SH, Fu ZR, Qiu W, Lv GY, Song RP, Wang JZ, Wang Z, Zhou J, Chen G, Zhao YP, Li L, Hu ZM, Luo QJ, Si ZZ, Xie B, He XS, Guo ZY, Zheng SS, Xu X. Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00171-5. [PMID: 34583911 DOI: 10.1016/j.hbpd.2021.09.001] [Reference Citation Analysis]
5 Berenguer M, Burra P, Ghobrial M, Hibi T, Metselaar H, Sapisochin G, Bhoori S, Kwan Man N, Mas V, Ohira M, Sangro B, van der Laan LJW. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1143-9. [PMID: 32217940 DOI: 10.1097/TP.0000000000003196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Tristán-Manzano M, Justicia-Lirio P, Maldonado-Pérez N, Cortijo-Gutiérrez M, Benabdellah K, Martin F. Externally-Controlled Systems for Immunotherapy: From Bench to Bedside. Front Immunol 2020;11:2044. [PMID: 33013864 DOI: 10.3389/fimmu.2020.02044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Zhou L, Pan LC, Zheng YG, Du GS, Fu XQ, Zhu ZD, Song JY, Liu ZJ, Su XZ, Chen W, Zheng DH, Suo LL, Yang SZ. Novel strategy of sirolimus plus thymalfasin and huaier granule on tumor recurrence of hepatocellular carcinoma beyond the UCSF criteria following liver transplantation: A single center experience.Oncol Lett. 2018;16:4407-4417. [PMID: 30214575 DOI: 10.3892/ol.2018.9226] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
8 Kolos JM, Voll AM, Bauder M, Hausch F. FKBP Ligands-Where We Are and Where to Go? Front Pharmacol 2018;9:1425. [PMID: 30568592 DOI: 10.3389/fphar.2018.01425] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
9 Ye Q, Ling S, Jiang G, Shan Q, Xu S, Zhan Q, Wu Y, Liu Y, Zheng S, Xu X. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria. Eur J Surg Oncol 2021:S0748-7983(21)00407-8. [PMID: 33902956 DOI: 10.1016/j.ejso.2021.04.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Au KP, Chok KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. World J Gastroenterol 2018; 24(45): 5081-5094 [PMID: 30568386 DOI: 10.3748/wjg.v24.i45.5081] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
11 Chen X, Wang DD, Xu H, Li ZP. Initial dose recommendation for sirolimus in paediatric kaposiform haemangioendothelioma patients based on population pharmacokinetics and pharmacogenomics. J Int Med Res 2020;48:300060520947627. [PMID: 32815764 DOI: 10.1177/0300060520947627] [Reference Citation Analysis]